Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Chief Scientific Officer | May 30, 2023 | June 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date May 30, 2023 · Filed June 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 225,316 |
Ending reported balance
After 2023-05-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-05-30 · Gift · Disposed 43,000 · Balance 321,316 F1: These transactions represent bona fide gifts from the Reporting Person to an adult child for which no consideration was paid. Row 2 · 2023-05-30 · Gift · Disposed 43,000 · Balance 278,316 F2: These transactions represent bona fide gifts from the Reporting Person to another adult child for which no consideration was paid. Row 3 · 2023-05-31 · Gift · Disposed 26,500 · Balance 251,816 F1: These transactions represent bona fide gifts from the Reporting Person to an adult child for which no consideration was paid. Row 4 · 2023-05-31 · Gift · Disposed 26,500 · Balance 225,316 F2: These transactions represent bona fide gifts from the Reporting Person to another adult child for which no consideration was paid. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions represent bona fide gifts from the Reporting Person to an adult child for which no consideration was paid.
F2: These transactions represent bona fide gifts from the Reporting Person to another adult child for which no consideration was paid.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2023 Filed Jun 1, 2023 20:27 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GiftCommon Stock | 26,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000054 · wk-form4_1685651220.xml · nonDerivative · entry 4 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,316 F2 · kind: These transactions represent bona fide gifts from the Reporting Person to another adult child for which no consideration was paid. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 20:27 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GiftCommon Stock | 26,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000054 · wk-form4_1685651220.xml · nonDerivative · entry 3 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,816 F1 · kind: These transactions represent bona fide gifts from the Reporting Person to an adult child for which no consideration was paid. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 20:27 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GiftCommon Stock | 43,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000054 · wk-form4_1685651220.xml · nonDerivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,316 F2 · kind: These transactions represent bona fide gifts from the Reporting Person to another adult child for which no consideration was paid. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 20:27 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GiftCommon Stock | 43,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000054 · wk-form4_1685651220.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,316 F1 · kind: These transactions represent bona fide gifts from the Reporting Person to an adult child for which no consideration was paid. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 20 | $1.11 | $22.23 |
DisclosureSEC source: 0001453687-23-000033 · wf-form4_167304333252079.xml · nonDerivative · entry 4 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,316 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,372 | $1.13 | $3,808.00 |
DisclosureSEC source: 0001453687-23-000033 · wf-form4_167304333252079.xml · nonDerivative · entry 3 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,336 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 11 | $1.15 | $12.60 |
DisclosureSEC source: 0001453687-23-000033 · wf-form4_167304333252079.xml · nonDerivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,708 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 6,381 | $1.13 | $7,234.14 |
DisclosureSEC source: 0001453687-23-000033 · wf-form4_167304333252079.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,719 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:01 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000018 · wf-form4_167286962791883.xml · derivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2033-01-01 F3 · derivative.exercise_date: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:01 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000018 · wf-form4_167286962791883.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,100 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027. F2 · balance_after: Includes 5,747 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2021 and February 28, 2022. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:18 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,416 | $3.09 | $10,541.43 |
DisclosureSEC source: 0001453687-22-000033 · wf-form4_164159029049282.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,353 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.99 to $3.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:34 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 340,000 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001453687-22-000020 · wf-form4_164141844549022.xml · derivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2032-01-02 F2 · derivative.exercise_date: This option vests as to 25% on January 3, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:34 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 72,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000020 · wf-form4_164141844549022.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,769 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 3, 2023. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 3, 2026. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:16 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,370 | $2.99 | $13,052.75 |
DisclosureSEC source: 0001453687-21-000185 · wf-form4_163952018706703.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,769 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $2.94 to $3.0201. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 22:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000175 · wf-form4_163917402992018.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,139 F1 · kind: On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 27,500 shares of the Issuer's common stock (the "Performance RSUs"), which were earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. The compensation committee of the board of directors of the Issuer has determined that the second of the performance conditions has been met, and accordingly 13,750 Performance RSUs vested on December 8, 2021. Read SEC document |
| October 13, 2021 Filed Oct 15, 2021 22:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 3,892 | $4.39 | $17,085.88 |
DisclosureSEC source: 0001453687-21-000143 · wf-form4_163433564708644.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,389 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.35 to $4.475. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:26 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000134 · wf-form4_163346556411169.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,281 F1 · kind: On January 4, 2021, the reporting person was granted performance based restricted stock units for an aggregate of 27,500 shares of the Issuer's common stock (the "Performance RSUs"), which may be earned based on the achievement of two separate performance conditions related to the Issuer's operating and research and development activities. Any Performance RSUs will generally vest in two equal installments upon the dates of achievement of each of the two performance conditions, subject to continued employment, so long as each performance condition is met before December 31, 2021. The compensation committee of the board of directors of the Issuer has determined that the first of the performance conditions has been met, and accordingly 13,750 Performance RSUs vested on October 1, 2021. F2 · balance_after: Includes 2,753 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between March 1, 2021 and August 31, 2021. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:24 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,629 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001453687-21-000064 · wf-form4_162076464438216.xml · derivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,629 shares Expires 2021-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested as of September 7, 2015. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:24 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 13,629 | $2.77 | $37,752.33 |
DisclosureSEC source: 0001453687-21-000064 · wf-form4_162076464438216.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:50 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001453687-21-000017 · wf-form4_160996979617224.xml · derivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2031-01-03 F2 · derivative.exercise_date: This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:50 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000017 · wf-form4_160996979617224.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,149 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 21:13 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001453687-20-000119 · wf-form4_160383317124280.xml · derivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,629 Underlying: Common Stock · 30,000 shares Expires 2021-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the option are fully vested. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 21:13 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 30,000 | $2.77 | $83,100.00 |
DisclosureSEC source: 0001453687-20-000119 · wf-form4_160383317124280.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,410 shares of common stock acquired on March 2, 2020 and 3,625 shares of common stock acquired on August 31, 2020, in each case under the issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001453687-20-000012 · wf-form4_157835925407457.xml · derivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 20:20 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001453687-19-000147 · wf-form4_157065239599056.xml · derivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-10-06 F1 · derivative.exercise_date: This option shall vest as to 50% of the shares on October 7, 2020, and the remaining 50% of the shares on October 7, 2021. Read SEC document |
| August 20, 2019 Filed Aug 20, 2019 20:31 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 50,000 | $1.81 | $90,500.00 |
DisclosureSEC source: 0001453687-19-000122 · wf-form4_156633309274523.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,114 Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $2.60 Strike: $2.60 | $260,000.00 |
DisclosureSEC source: 0001453687-19-000011 · wf-form4_154698234281465.xml · derivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-06 F1 · derivative.exercise_date: This option will vest as to 25% on January 7, 2020. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2019 Filed Feb 21, 2019 21:29 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 36,114 | $2.77 Strike: $2.77 | $100,035.78 |
DisclosureSEC source: 0001676930-19-000002 · wf-form4_155078458301932.xml · derivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,629 Underlying: Common Stock · 36,114 shares Expires 2021-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying the option are fully vested. Read SEC document |
| January 07, 2019 Filed Feb 21, 2019 21:29 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 36,114 | $2.77 | $100,035.78 |
DisclosureSEC source: 0001676930-19-000002 · wf-form4_155078458301932.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 23:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001638599-18-000680 · doc4_5477.xml · derivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:45 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $19.33 | $0.00 |
DisclosureSEC source: 0001638599-17-000701 · doc4_4845.xml · derivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: This option vests as to 25% of the shares on June 16, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 23:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001104659-16-164625 · a4.xml · derivative · entry 3 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,743 Underlying: Common Stock · 10,000 shares Expires 2021-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying the option are fully vested. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 23:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 10,000 | $17.55 | $175,500.00 |
DisclosureSEC source: 0001104659-16-164625 · a4.xml · nonDerivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 23:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 10,000 | $2.77 | $27,700.00 |
DisclosureSEC source: 0001104659-16-164625 · a4.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.